inositol has been researched along with Acute Confusional Senile Dementia in 133 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 9.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 9.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 7.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "Previous studies suggest the presence of increased concentrations of cerebral myo-inositol in Alzheimer disease (AD)." | 7.69 | Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. ( Holloway, HW; Schapiro, MB; Shetty, HU, 1996) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 5.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 5.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 3.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| " Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups." | 3.77 | Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. ( Archer, N; Beacher, F; Daly, E; Foy, CML; Lamar, M; Lovestone, S; Morris, RG; Murphy, DGM; Murphy, KC; Poppe, M; Prasher, V; Simmons, A, 2011) |
| "In this study, cognitively intact chronic hypertensive older patients had a higher white matter myoinositol/creatine ratio compared with healthy older subjects, suggesting that myoinositol may be a sensitive marker of the effects of chronic hypertension on the brain." | 3.71 | Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. ( Benedetti, C; Catani, M; Cherubini, A; Howard, R; Mariani, E; Mecocci, P; Metastasio, A; Pelliccioli, GP; Senin, U; Tarducci, R, 2002) |
| " Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects." | 3.69 | Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997) |
| "Previous studies suggest the presence of increased concentrations of cerebral myo-inositol in Alzheimer disease (AD)." | 3.69 | Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. ( Holloway, HW; Schapiro, MB; Shetty, HU, 1996) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Mean Alzheimer's Disease Assessment Scale cognitive subscale scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and 24." | 2.71 | Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. ( Charles, HC; Doraiswamy, PM; Ieni, JR; Krishnan, KR; Mintzer, J; Perdomo, C; Rogers, S; Weisler, R; Yu, X, 2003) |
| "Inositol is a simple polyol precursor in a second messenger system important in the brain." | 2.68 | Controlled trials of inositol in psychiatry. ( Levine, J, 1997) |
| "Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS." | 2.42 | 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. ( Jones, RS; Waldman, AD, 2004) |
| "myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline." | 2.41 | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. ( Firbank, MJ; Harrison, RM; O'Brien, JT, 2002) |
| "Brain damage associated with Alzheimer's disease (AD) occurs even decades before the symptomatic onset, raising the need to investigate its progression from prodromal stages." | 1.72 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022) |
| "Failure of Alzheimer's disease clinical trials to improve or stabilize cognition has led to the need for a better understanding of the driving forces behind cognitive decline in the presence of active disease processes." | 1.56 | Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid-β attenuation. ( Bazzigaluppi, P; Beckett, TL; Hill, ME; Koletar, MM; McLaurin, J; Morrone, CD; Stefanovic, B, 2020) |
| " Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime." | 1.46 | A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes. ( Chung, SK; Das, S; Jung, HY; Kim, KT; Kim, YK; Lee, D; Lee, J; Lee, WS; Lim, S; Luo, W, 2017) |
| "Amnestic mild cognitive impairment (aMCI) is often the prodromal stage to AD." | 1.43 | (1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease. ( Chen, W; Chen, X; Guo, Z; Hou, H; Liu, X; Shen, Y; Wei, F, 2016) |
| "The genetic etiology of late-onset Alzheimer's disease (LOAD) has proven complex, involving clinical and genetic heterogeneity and gene-gene interactions." | 1.40 | Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size. ( Hohman, TJ; Koran, ME; Meda, SA; Thornton-Wells, TA, 2014) |
| "Myo-inositol (mIns) is a marker of glial cells proliferation and has been shown to increase in early Alzheimer's disease (AD) pathology." | 1.39 | MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease. ( Cai, K; Crescenzi, R; Hariharan, H; Haris, M; Kogan, F; Nath, K; Reddy, R; Singh, A, 2013) |
| "Agitation and depression are among the commonest behavioural and psychological symptoms exhibited by Alzheimer's disease patients." | 1.39 | Differences in brain metabolism associated with agitation and depression in Alzheimer's disease. ( Fuh, JL; Hung, CW; Lirng, JF; Tsai, CF; Wang, SJ, 2013) |
| "The diagnosis of mild or questionable Alzheimer's disease (AD) depends on clinical criteria that often leave a margin for doubt." | 1.37 | Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. ( Andreiuolo, PA; Bottino, CM; de Oliveira-Souza, R; Moll, J; Silveira de Souza, A; Tovar-Moll, F, 2011) |
| "Inositol is a simple polyol with eight naturally occurring stereoisomers." | 1.34 | Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. ( Brown, M; Fenili, D; McLaurin, J; Rappaport, R, 2007) |
| "The cognitive decline in Alzheimer's disease (AD) patients has been reported to involve alterations in the medial temporal lobe and the posterior cingulate gyrus." | 1.34 | A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. ( Horiguchi, J; Inagaki, T; Inami, Y; Kawamukai, T; Miyaoka, T; Okazaki, S; Shinno, H; Utani, E, 2007) |
| "Given the available therapies for Alzheimer's disease, early diagnosis is of paramount importance." | 1.33 | Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. ( Fayed, N; Modrego, PJ; Pina, MA, 2005) |
| "Despite progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged." | 1.33 | Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. ( Cleary, JP; Hofmeister, J; Lesne, S; Mehta, T; O'Hare, E; Selkoe, DJ; Townsend, M; Walsh, DM, 2006) |
| "Furthermore, patients suffering from vascular dementia (VD) had remarkably enhanced TMA/tCr ratios, potentially due to ongoing degradation of myelin." | 1.32 | Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. ( Dierks, T; Frölich, L; Gorriz, C; Herminghaus, S; Lanfermann, H; Maurer, K; Pilatus, U; Wittsack, HJ; Zanella, FE, 2003) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| "Inositol has 8 stereoisomers, four of which are physiologically active." | 1.31 | Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. ( Antel, JP; Fraser, PE; Golomb, R; Jurewicz, A; McLaurin, J, 2000) |
| "The bradykinin-induced increase in APPs secretion in PC-12 cells was mediated by protein kinase C (PKC), whereas vasopressin receptors in NRK-49F cells were coupled to APP processing by PKC-independent signalling pathways." | 1.30 | Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. ( Growdon, JH; Kim, C; Nitsch, RM, 1998) |
| "A key pathological feature of Alzheimer's disease is the formation and accumulation of amyloid fibres." | 1.30 | Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. ( Chakrabartty, A; Franklin, T; Fraser, PE; McLaurin, J, 1998) |
| "In contrast, trisomy 21 did not affect the uptake of choline, serine or glucose." | 1.28 | Down's syndrome fibroblasts exhibit enhanced inositol uptake. ( Fruen, BR; Lester, BR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.75) | 18.7374 |
| 1990's | 22 (16.54) | 18.2507 |
| 2000's | 42 (31.58) | 29.6817 |
| 2010's | 55 (41.35) | 24.3611 |
| 2020's | 13 (9.77) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Zhang, G | 1 |
| Hawkes, CA | 3 |
| Shaw, JE | 3 |
| McLaurin, J | 13 |
| Nitz, M | 4 |
| Bulic, B | 1 |
| Pickhardt, M | 1 |
| Mandelkow, E | 1 |
| Barrera Guisasola, EE | 1 |
| Andujar, SA | 1 |
| Hubin, E | 1 |
| Broersen, K | 1 |
| Kraan, IM | 1 |
| Méndez, L | 1 |
| Delpiccolo, CM | 1 |
| Masman, MF | 1 |
| Rodríguez, AM | 1 |
| Enriz, RD | 1 |
| Hone-Blanchet, A | 1 |
| Bohsali, A | 1 |
| Krishnamurthy, LC | 1 |
| Shahid, S | 1 |
| Lin, Q | 1 |
| Zhao, L | 1 |
| Loring, D | 1 |
| Goldstein, F | 1 |
| John, SE | 1 |
| Fleischer, CC | 1 |
| Levey, A | 1 |
| Lah, J | 1 |
| Qiu, D | 1 |
| Crosson, B | 1 |
| Shad, KF | 1 |
| Soubra, W | 1 |
| Cordato, DJ | 1 |
| Correia, SC | 1 |
| Alves, MG | 1 |
| Oliveira, PF | 1 |
| Casadesus, G | 1 |
| LaManna, J | 1 |
| Perry, G | 1 |
| Moreira, PI | 1 |
| López-Gambero, AJ | 1 |
| Pacheco-Sánchez, B | 1 |
| Rosell-Valle, C | 1 |
| Medina-Vera, D | 1 |
| Navarro, JA | 1 |
| Fernández-Arjona, MDM | 1 |
| de Ceglia, M | 1 |
| Sanjuan, C | 1 |
| Simon, V | 1 |
| Cota, D | 1 |
| Rivera, P | 1 |
| Rodríguez de Fonseca, F | 1 |
| Suárez, J | 1 |
| Gozdas, E | 1 |
| Hinkley, L | 1 |
| Fingerhut, H | 1 |
| Dacorro, L | 1 |
| Gu, M | 1 |
| Sacchet, MD | 1 |
| Hurd, R | 1 |
| Hosseini, SMH | 1 |
| Muñoz-Moreno, E | 1 |
| Simões, RV | 1 |
| Tudela, R | 1 |
| López-Gil, X | 1 |
| Soria, G | 1 |
| Hill, MA | 1 |
| Gammie, SC | 1 |
| Yoshida, KI | 3 |
| Ishikawa, S | 3 |
| Morrone, CD | 1 |
| Bazzigaluppi, P | 1 |
| Beckett, TL | 1 |
| Hill, ME | 1 |
| Koletar, MM | 1 |
| Stefanovic, B | 2 |
| Michon, C | 1 |
| Kang, CM | 1 |
| Karpenko, S | 1 |
| Tanaka, K | 3 |
| Rashid, S | 1 |
| Bhat, BA | 1 |
| Mehta, G | 1 |
| Peña-Bautista, C | 1 |
| Torres-Cuevas, I | 1 |
| Baquero, M | 1 |
| Ferrer, I | 1 |
| García, L | 1 |
| Vento, M | 1 |
| Cháfer-Pericás, C | 1 |
| Lu, L | 1 |
| Zheng, X | 1 |
| Wang, S | 1 |
| Tang, C | 1 |
| Zhang, Y | 1 |
| Yao, G | 1 |
| Zeng, J | 1 |
| Ge, S | 1 |
| Wen, H | 1 |
| Xu, M | 1 |
| Guyatt, G | 1 |
| Xu, N | 1 |
| Ramp, P | 1 |
| Lehnert, A | 1 |
| Matamouros, S | 1 |
| Wirtz, A | 1 |
| Baumgart, M | 1 |
| Bott, M | 1 |
| Natsume, A | 1 |
| Takenaka, S | 3 |
| Waragai, M | 1 |
| Moriya, M | 1 |
| Nojo, T | 1 |
| Liu, M | 1 |
| Jevtic, S | 1 |
| Markham-Coultes, K | 1 |
| Ellens, NPK | 1 |
| O'Reilly, MA | 1 |
| Hynynen, K | 1 |
| Aubert, I | 2 |
| Lee, D | 1 |
| Lee, WS | 1 |
| Lim, S | 1 |
| Kim, YK | 1 |
| Jung, HY | 1 |
| Das, S | 1 |
| Lee, J | 1 |
| Luo, W | 1 |
| Kim, KT | 1 |
| Chung, SK | 1 |
| Joe, E | 1 |
| Medina, LD | 1 |
| Ringman, JM | 1 |
| O'Neill, J | 1 |
| Yanez Lopez, M | 1 |
| Pardon, MC | 1 |
| Baiker, K | 1 |
| Prior, M | 1 |
| Yuchun, D | 1 |
| Agostini, A | 1 |
| Bai, L | 1 |
| Auer, DP | 1 |
| Faas, HM | 1 |
| Kantarci, K | 5 |
| Menezes, TL | 1 |
| Andrade-Valença, LP | 1 |
| Valença, MM | 1 |
| Thomason, LA | 2 |
| Koran, ME | 1 |
| Hohman, TJ | 1 |
| Meda, SA | 1 |
| Thornton-Wells, TA | 1 |
| Tsai, CF | 1 |
| Hung, CW | 1 |
| Lirng, JF | 1 |
| Wang, SJ | 1 |
| Fuh, JL | 1 |
| Aytan, N | 1 |
| Choi, JK | 1 |
| Carreras, I | 1 |
| Kowall, NW | 1 |
| Jenkins, BG | 1 |
| Dedeoglu, A | 1 |
| Bleiholder, C | 1 |
| Do, TD | 1 |
| Wu, C | 1 |
| Economou, NJ | 1 |
| Bernstein, SS | 1 |
| Buratto, SK | 1 |
| Shea, JE | 1 |
| Bowers, MT | 1 |
| Marjańska, M | 1 |
| Weigand, SD | 2 |
| Preboske, G | 1 |
| Wengenack, TM | 1 |
| Chamberlain, R | 1 |
| Curran, GL | 1 |
| Poduslo, JF | 1 |
| Garwood, M | 1 |
| Kobayashi, D | 1 |
| Lin, JC | 1 |
| Jack, CR | 5 |
| Tajima, S | 1 |
| Yoshida, K | 2 |
| Bolognin, S | 1 |
| Buffelli, M | 1 |
| Puoliväli, J | 1 |
| Iqbal, K | 1 |
| Kumar, S | 1 |
| Shinno, H | 2 |
| Inagaki, T | 2 |
| Miyaoka, T | 2 |
| Okazaki, S | 2 |
| Kawamukai, T | 2 |
| Utani, E | 2 |
| Inami, Y | 2 |
| Horiguchi, J | 2 |
| Suriyajakryuththana, W | 1 |
| Tuntiyatorn, L | 1 |
| Teepprasarn, N | 1 |
| Sukying, C | 1 |
| Wang, P | 1 |
| Ding, K | 1 |
| Wang, H | 1 |
| Raleigh, DP | 1 |
| Murray, ME | 1 |
| Przybelski, SA | 1 |
| Lesnick, TG | 1 |
| Liesinger, AM | 1 |
| Spychalla, A | 1 |
| Zhang, B | 1 |
| Gunter, JL | 1 |
| Parisi, JE | 1 |
| Boeve, BF | 4 |
| Knopman, DS | 3 |
| Petersen, RC | 4 |
| Dickson, DW | 1 |
| Doert, A | 1 |
| Pilatus, U | 3 |
| Zanella, F | 1 |
| Müller, WE | 1 |
| Eckert, GP | 1 |
| Jin, M | 1 |
| Selkoe, DJ | 2 |
| Brener, O | 1 |
| Dunkelmann, T | 1 |
| Gremer, L | 1 |
| van Groen, T | 1 |
| Mirecka, EA | 1 |
| Kadish, I | 1 |
| Willuweit, A | 1 |
| Kutzsche, J | 1 |
| Jürgens, D | 1 |
| Rudolph, S | 1 |
| Tusche, M | 1 |
| Bongen, P | 1 |
| Pietruszka, J | 1 |
| Oesterhelt, F | 1 |
| Langen, KJ | 1 |
| Demuth, HU | 1 |
| Janssen, A | 1 |
| Hoyer, W | 1 |
| Funke, SA | 1 |
| Nagel-Steger, L | 1 |
| Willbold, D | 1 |
| Guo, Z | 2 |
| Zhang, J | 1 |
| Liu, X | 2 |
| Hou, H | 2 |
| Cao, Y | 1 |
| Wei, F | 2 |
| Li, J | 1 |
| Chen, X | 2 |
| Shen, Y | 2 |
| Chen, W | 2 |
| Voevodskaya, O | 1 |
| Sundgren, PC | 1 |
| Strandberg, O | 1 |
| Zetterberg, H | 1 |
| Minthon, L | 1 |
| Blennow, K | 1 |
| Wahlund, LO | 1 |
| Westman, E | 1 |
| Hansson, O | 1 |
| Su, L | 1 |
| Blamire, AM | 1 |
| Watson, R | 1 |
| He, J | 1 |
| Hayes, L | 1 |
| O'Brien, JT | 2 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Watanabe, T | 2 |
| Shiino, A | 2 |
| Akiguchi, I | 2 |
| Thambisetty, M | 1 |
| Hye, A | 1 |
| Foy, C | 1 |
| Daly, E | 2 |
| Glover, A | 2 |
| Cooper, A | 1 |
| Simmons, A | 3 |
| Murphy, D | 1 |
| Lovestone, S | 3 |
| Wang, Z | 1 |
| Zhao, C | 1 |
| Yu, L | 1 |
| Zhou, W | 1 |
| Li, K | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 2 |
| Maurer, K | 2 |
| Zanella, FE | 2 |
| Lanfermann, H | 2 |
| Pantel, J | 1 |
| Rupsingh, R | 3 |
| Borrie, M | 1 |
| Smith, M | 3 |
| Wells, JL | 3 |
| Bartha, R | 3 |
| Dasilva, KA | 1 |
| Penner, J | 1 |
| Borrie, MJ | 2 |
| Deng, LH | 1 |
| Chen, SQ | 2 |
| Wang, PJ | 3 |
| Ten, GJ | 1 |
| Zhan, W | 1 |
| Li, MH | 2 |
| Zang, FC | 2 |
| Foy, CM | 1 |
| Daly, EM | 2 |
| O'Gorman, R | 1 |
| Murphy, DG | 1 |
| Lamar, M | 1 |
| Foy, CML | 1 |
| Beacher, F | 1 |
| Poppe, M | 1 |
| Archer, N | 1 |
| Prasher, V | 1 |
| Murphy, KC | 1 |
| Morris, RG | 1 |
| Murphy, DGM | 1 |
| Wang, T | 1 |
| Xiao, S | 1 |
| Li, X | 1 |
| Ding, B | 1 |
| Ling, H | 1 |
| Chen, K | 1 |
| Fang, Y | 1 |
| Fenili, D | 3 |
| Weng, YQ | 1 |
| Yamaoka, M | 1 |
| Osawa, S | 1 |
| Morinaga, T | 1 |
| Salloway, S | 1 |
| Sperling, R | 1 |
| Keren, R | 1 |
| Porsteinsson, AP | 1 |
| van Dyck, CH | 1 |
| Tariot, PN | 1 |
| Gilman, S | 1 |
| Arnold, D | 1 |
| Abushakra, S | 1 |
| Hernandez, C | 1 |
| Crans, G | 1 |
| Liang, E | 1 |
| Quinn, G | 1 |
| Bairu, M | 1 |
| Pastrak, A | 1 |
| Cedarbaum, JM | 1 |
| Walecki, J | 1 |
| Barcikowska, M | 1 |
| Ćwikła, JB | 1 |
| Gabryelewicz, T | 1 |
| Forster, DM | 1 |
| James, MF | 1 |
| Williams, SR | 1 |
| Deng, L | 1 |
| Silveira de Souza, A | 1 |
| de Oliveira-Souza, R | 1 |
| Moll, J | 1 |
| Tovar-Moll, F | 1 |
| Andreiuolo, PA | 1 |
| Bottino, CM | 2 |
| Shirakashi, Y | 1 |
| Kotani, E | 1 |
| Yoshimura, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Mlynárik, V | 1 |
| Cacquevel, M | 1 |
| Sun-Reimer, L | 1 |
| Janssens, S | 1 |
| Cudalbu, C | 1 |
| Lei, H | 1 |
| Schneider, BL | 1 |
| Aebischer, P | 1 |
| Gruetter, R | 1 |
| Lim, TS | 1 |
| Hong, YH | 1 |
| Lee, HY | 1 |
| Choi, JY | 1 |
| Kim, HS | 1 |
| Moon, SY | 1 |
| Lai, AY | 1 |
| Cai, Q | 1 |
| Shen, YY | 1 |
| Teng, GJ | 1 |
| Zhang, W | 2 |
| Ma, K | 1 |
| Nilsen, LH | 1 |
| Melø, TM | 1 |
| Saether, O | 1 |
| Witter, MP | 1 |
| Sonnewald, U | 1 |
| Haris, M | 1 |
| Singh, A | 1 |
| Cai, K | 1 |
| Nath, K | 1 |
| Crescenzi, R | 1 |
| Kogan, F | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Wang, GL | 1 |
| Li, P | 1 |
| Gao, XL | 1 |
| Firbank, MJ | 1 |
| Harrison, RM | 1 |
| Catani, M | 2 |
| Mecocci, P | 2 |
| Tarducci, R | 3 |
| Howard, R | 2 |
| Pelliccioli, GP | 3 |
| Mariani, E | 1 |
| Metastasio, A | 1 |
| Benedetti, C | 1 |
| Senin, U | 3 |
| Cherubini, A | 2 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Gonen, O | 1 |
| Reynolds, G | 1 |
| Edland, SD | 2 |
| Smith, GE | 3 |
| Ivnik, RJ | 3 |
| Tangalos, EG | 3 |
| Waldman, AD | 3 |
| Rai, GS | 1 |
| Herminghaus, S | 1 |
| Gorriz, C | 1 |
| Dierks, T | 1 |
| Wittsack, HJ | 1 |
| Pilcher, HR | 1 |
| Krishnan, KR | 2 |
| Charles, HC | 2 |
| Doraiswamy, PM | 1 |
| Mintzer, J | 1 |
| Weisler, R | 1 |
| Yu, X | 1 |
| Perdomo, C | 1 |
| Ieni, JR | 1 |
| Rogers, S | 1 |
| Jones, RS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 2 |
| Ferman, TJ | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Hancu, I | 1 |
| Zimmerman, EA | 1 |
| Sailasuta, N | 1 |
| Hurd, RE | 1 |
| Modrego, PJ | 1 |
| Fayed, N | 1 |
| Pina, MA | 1 |
| Maestú, F | 2 |
| García-Segura, J | 1 |
| Ortiz, T | 2 |
| Montoya, J | 2 |
| Fernández, A | 2 |
| Gil-Gregorio, P | 2 |
| Campo, P | 2 |
| Fernández, S | 1 |
| Viaño, J | 2 |
| Portera, A | 1 |
| García-Segura, JM | 1 |
| Azevedo, D | 1 |
| Tatsch, M | 1 |
| Hototian, SR | 1 |
| Bazzarella, MC | 1 |
| Castro, CC | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Townsend, M | 1 |
| Cleary, JP | 1 |
| Mehta, T | 1 |
| Hofmeister, J | 1 |
| Lesne, S | 1 |
| O'Hare, E | 1 |
| Walsh, DM | 1 |
| Brown, M | 1 |
| Rappaport, R | 1 |
| Griffith, HR | 1 |
| den Hollander, JA | 1 |
| Stewart, CC | 1 |
| Evanochko, WT | 1 |
| Buchthal, SD | 1 |
| Harrell, LE | 1 |
| Zamrini, EY | 1 |
| Brockington, JC | 1 |
| Marson, DC | 1 |
| Gellermann, GP | 1 |
| Ullrich, K | 1 |
| Unger, C | 1 |
| Fändrich, M | 1 |
| Sauter, S | 1 |
| Diekmann, S | 1 |
| Yue, Y | 1 |
| Hu, L | 1 |
| Tian, QJ | 1 |
| Jiang, JM | 1 |
| Dong, YL | 1 |
| Jin, ZY | 1 |
| Cheng, YH | 1 |
| Hong, X | 1 |
| Ge, QS | 1 |
| Zuo, PP | 1 |
| Rami, L | 1 |
| Gómez-Ansón, B | 1 |
| Bosch, B | 1 |
| Sánchez-Valle, R | 1 |
| Monte, GC | 1 |
| Villar, A | 1 |
| Molinuevo, JL | 1 |
| Okada, T | 1 |
| Sakamoto, S | 1 |
| Nakamoto, Y | 1 |
| Kohara, N | 1 |
| Senda, M | 1 |
| Rylett, J | 1 |
| Shonk, T | 3 |
| Ross, BD | 6 |
| Mohanakrishnan, P | 1 |
| Fowler, AH | 1 |
| Vonsattel, JP | 1 |
| Husain, MM | 1 |
| Jolles, PR | 1 |
| Liem, P | 1 |
| Komoroski, RA | 1 |
| Resnick, SM | 1 |
| Costa, PT | 1 |
| Shonk, TK | 2 |
| Moats, RA | 4 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Dunbar, PG | 1 |
| Durant, GJ | 1 |
| Rho, T | 1 |
| Ojo, B | 1 |
| Huzl, JJ | 1 |
| Smith, DA | 1 |
| el-Assadi, AA | 1 |
| Sbeih, S | 1 |
| Ngur, DO | 1 |
| Periyasamy, S | 1 |
| Ernst, T | 3 |
| Miller, BL | 1 |
| Woolley, S | 1 |
| Parnetti, L | 1 |
| Lowenthal, DT | 1 |
| Presciutti, O | 1 |
| Palumbo, R | 1 |
| Gobbi, G | 2 |
| Chiarini, P | 1 |
| Palumbo, B | 1 |
| Shetty, HU | 3 |
| Holloway, HW | 1 |
| Schapiro, MB | 3 |
| Barak, Y | 1 |
| Levine, J | 2 |
| Glasman, A | 1 |
| Elizur, A | 1 |
| Belmaker, RH | 1 |
| Heun, R | 1 |
| Schlegel, S | 1 |
| Graf-Morgenstern, M | 1 |
| Tintera, J | 1 |
| Gawehn, J | 1 |
| Stoeter, P | 1 |
| Chang, L | 2 |
| Melchor, R | 1 |
| Mehringer, CM | 1 |
| Nitsch, RM | 1 |
| Kim, C | 1 |
| Growdon, JH | 1 |
| Franklin, T | 1 |
| Chakrabartty, A | 1 |
| Fraser, PE | 2 |
| Laubenberger, J | 1 |
| Bayer, S | 1 |
| Thiel, T | 1 |
| Hennig, J | 1 |
| Langer, M | 1 |
| Lazeyras, F | 1 |
| Tupler, LA | 1 |
| Erickson, R | 1 |
| Boyko, OB | 1 |
| Bluml, S | 1 |
| Cowan, R | 1 |
| Danielsen, E | 1 |
| Farrow, N | 1 |
| Tan, J | 1 |
| Salvan, AM | 1 |
| Ceccaldi, M | 1 |
| Confort-Gouny, S | 1 |
| Milandre, C | 1 |
| Cozzone, PJ | 1 |
| Vion-Dury, J | 1 |
| Huang, W | 2 |
| Alexander, GE | 2 |
| Krasuski, JS | 2 |
| Rapoport, SI | 2 |
| Golomb, R | 1 |
| Jurewicz, A | 1 |
| Antel, JP | 1 |
| Xu, YC | 1 |
| Campeau, NG | 1 |
| Kokmen, E | 1 |
| Yagyu, K | 1 |
| Kitagawa, K | 1 |
| Irie, T | 1 |
| Wu, B | 1 |
| Zeng, XT | 1 |
| Hattori, N | 1 |
| Inagaki, C | 1 |
| Piccirilli, M | 1 |
| Van Nostrand, WE | 1 |
| Melchor, JP | 1 |
| Engelhardt, E | 1 |
| Moreira, DM | 1 |
| Laks, J | 1 |
| Marinho, VM | 1 |
| Rozenthal, M | 1 |
| Oliveira, AC | 1 |
| Fruen, BR | 1 |
| Lester, BR | 1 |
| Stokes, CE | 1 |
| Hawthorne, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach[NCT01208675] | 1,150 participants (Actual) | Observational | 2010-09-30 | Active, not recruiting | |||
| In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.[NCT05753228] | 90 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder[NCT02811133] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-31 | Withdrawn (stopped due to Funding terminated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
13 reviews available for inositol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; P | 2013 |
Alzheimer's disease large-scale gene expression portrait identifies exercise as the top theoretical treatment.
Topics: Alzheimer Disease; Curcumin; Female; Fluoxetine; Gene Expression; Humans; Inositol; Interferons; Mal | 2022 |
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anx | 2020 |
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cerebral Hemorrha | 2013 |
Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clinical Trials as Topic; Glycosaminoglycans; Heparin, Low | 2014 |
Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Flavonoids; Grape Seed Extract; Humans; Inositol; | 2010 |
scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biological Availability; Clinical Trials as Topic; Drug Evaluation, Prec | 2012 |
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Choline; Humans; Inositol; Magnetic Resonance Spectroscopy; | 2002 |
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Dementia, Vascular; Glutamic Acid; | 2004 |
In vivo MR spectroscopy of human dementia.
Topics: Alzheimer Disease; Brain Chemistry; Humans; Inositol; Magnetic Resonance Spectroscopy | 1998 |
Real or imaginary? Human metabolism through nuclear magnetism.
Topics: Alzheimer Disease; Animals; Brain; Down Syndrome; Glutamic Acid; History, 20th Century; Humans; In V | 2000 |
[Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; | 2001 |
10 trials available for inositol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cholinesterase In | 2010 |
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprot | 2011 |
The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Brain Ischemia; Dementia, Vascular; Female; | 2012 |
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Cholinesterase Inhibitors; Done | 2003 |
High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cholinesterase | 2008 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; | 1996 |
Controlled trials of inositol in psychiatry.
Topics: Adult; Alzheimer Disease; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; Male; | 1997 |
110 other studies available for inositol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Carbohydrate Conformation; Inositol | 2008 |
New mimetic peptides inhibitors of Αβ aggregation. Molecular guidance for rational drug design.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Hydrophobic and Hydrophilic Interacti | 2015 |
Relationships between frontal metabolites and Alzheimer's disease biomarkers in cognitively normal older adults.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognition; Creatine; Fem | 2022 |
The Auditory Afferent Pathway as a Clinical Marker of Alzheimer's Disease.
Topics: Acoustic Stimulation; Afferent Pathways; Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Cerebra | 2022 |
Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; DNA, Mitochondrial; Glial Fibrillary Acidic Prot | 2022 |
Dietary administration of D-chiro-inositol attenuates sex-specific metabolic imbalances in the 5xFAD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Female; Humans; Inositol; Insulin; Insulin Resis | 2022 |
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition; Cognitive Dysfunction; Creatine; Glutamic Acid; H | 2022 |
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G | 2022 |
Production of scyllo-Inositol: Conversion of Rice Bran into a Promising Disease-Modifying Therapeutic Agent for Alzheimer's Disease.
Topics: 6-Phytase; Alzheimer Disease; Bacillus subtilis; Escherichia coli; Inositol; NADP; Oryza; Oxidoreduc | 2019 |
Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid-β attenuation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Cognition; Disease Models, Anim | 2020 |
A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer's disease.
Topics: Alzheimer Disease; Bacillus subtilis; Bacterial Proteins; Cloning, Molecular; Gene Silencing; Glucos | 2020 |
Conceptualization and Synthesis of the First Inosito-Inositol (Decahydroxydecalin, DHD): In silico Binding to β-Amyloid Protein.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Computer Simulation; Concept Formation; Humans; Inositol | 2020 |
Early neurotransmission impairment in non-invasive Alzheimer Disease detection.
Topics: Acetylcholine; Aged; Alzheimer Disease; Amino Acids; Biomarkers; Cognitive Dysfunction; Creatine; Fe | 2020 |
Metabolic engineering of Corynebacterium glutamicum for production of scyllo-inositol, a drug candidate against Alzheimer's disease.
Topics: Alzheimer Disease; Bacillus subtilis; Corynebacterium glutamicum; Humans; Inositol; Metabolic Engine | 2021 |
A new-generation of Bacillus subtilis cell factory for further elevated scyllo-inositol production.
Topics: Alzheimer Disease; Bacillus subtilis; Culture Media; Escherichia coli; Genes, Bacterial; Inositol; N | 2017 |
Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Cognitive Dysfunction; Diseas | 2017 |
Investigating the efficacy of a combination Aβ-targeted treatment in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barri | 2018 |
A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain; Cognition; Gliosis; G | 2017 |
Topics: Adult; Alzheimer Disease; Brain; Choline; Creatine; Cross-Sectional Studies; Female; Glutamic Acid; | 2019 |
Myoinositol CEST signal in animals with increased Iba-1 levels in response to an inflammatory challenge-Preliminary findings.
Topics: Alzheimer Disease; Animals; Calcium-Binding Proteins; Disease Models, Animal; Female; Image Interpre | 2019 |
Magnetic resonance imaging study cannot individually distinguish individuals with mild cognitive impairment, mild Alzheimer's disease, and normal aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Di | 2013 |
Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Down-Regulation; Enzymes; Female; | 2014 |
Differences in brain metabolism associated with agitation and depression in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Depression; Female; Gyrus Cinguli; Humans | 2013 |
Combination therapy in a transgenic model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Drug Therapy | 2013 |
Ion mobility spectrometry reveals the mechanism of amyloid formation of Aβ(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Humans; Inositol; Mass Spectrometry; Models, Mol | 2013 |
Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2014 |
An improved Bacillus subtilis cell factory for producing scyllo-inositol, a promising therapeutic agent for Alzheimer's disease.
Topics: Alzheimer Disease; Bacillus subtilis; Humans; Inositol; Stereoisomerism | 2013 |
Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.
Topics: Administration, Oral; Aging; Alzheimer Disease; Animals; Ciliary Neurotrophic Factor; Cognition Diso | 2014 |
Comment re: Journal of the Neurological Sciences 260 (2007) 132-138, PMID 17540407.
Topics: Alzheimer Disease; Aspartic Acid; Female; Gyrus Cinguli; Humans; Inositol; Male | 2014 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Alzheimer Disease; Aspartic Acid; Female; Gyrus Cinguli; Humans; Inositol; Male | 2014 |
Proton magnetic resonance spectroscopy in mild cognitive impairment and Alzheimer's disease: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2014 |
General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid; Diabetes Mellitus, Type 2; Inositol; Islet Amyloid | 2014 |
Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.
Topics: Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Astrocytes; Biomarkers; | 2014 |
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2015 |
Systematic analysis of time-dependent neural effects of soluble amyloid β oligomers in culture and in vivo: Prevention by scyllo-inositol.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cells, Cultured; Hippocampus; Humans; Inos | 2015 |
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carrier Proteins; Catechin; Disease Models, Anima | 2015 |
Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Depressive Disorder; Female; | 2015 |
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Amyloidogenic Proteins; Apolipoprotein E4; Aspartic Acid; Brain; Brain Mapp | 2016 |
(1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; Dominance, Cerebra | 2016 |
Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cre | 2016 |
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.
Topics: Aged; alpha-Macroglobulins; Alzheimer Disease; Aspartic Acid; Biomarkers; Complement Factor H; Disea | 2008 |
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Dominance, | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Reduced hippocampal glutamate in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Choline; Creatine; Female; Glutamic Acid; Hi | 2011 |
Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Cognition; Female; Hydrogen Bonding; Ino | 2010 |
Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Biomarkers; Brain Chemi | 2009 |
Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2011 |
Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Studies; Dementia; Down Syndro | 2011 |
Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cognitive Dysfunction; | 2012 |
Sodium/myo-Inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology.
Topics: Aging; Alzheimer Disease; Amyloid; Animals; Biological Transport; Brain; Gene Expression Regulation, | 2011 |
A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease.
Topics: Alzheimer Disease; Bacillus subtilis; Genetic Engineering; Humans; Inositol; Mutation; Stereoisomeri | 2011 |
N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI).
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Disease Progression; Female; | 2011 |
Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by ¹H MRS in vitro.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Glycery | 2012 |
In vivo uptake of β-amyloid by non-plaque associated microglia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Enzyme-Linked Immu | 2012 |
Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dys | 2011 |
Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease.
Topics: Adenosine Triphosphate; Algorithms; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Chemistr | 2012 |
Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Disease Pr | 2012 |
Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Brain; Disease Models, Animal; Inosito | 2012 |
Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Cholin | 2012 |
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Choline; Cre | 2012 |
MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Brain Mapping | 2013 |
1H-MRS assessment of the therapeutic effect of bilateral intraventricular BDNF infusion into APP/PS1 double transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2013 |
Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine | 2002 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Higher field strength for proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Cognition Disorders; Creatinine; Humans; Inositol; Ma | 2003 |
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Dementia, Vascular; Energy Metabolism; Female; Glutamic Aci | 2003 |
Drug research: the ups and downs of lithium.
Topics: Affect; Alzheimer Disease; Animals; Bipolar Disorder; Brain; Glycogen Synthase Kinase 3; Humans; Ino | 2003 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain C | 2005 |
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Cohort Studies; Creatin | 2005 |
Evidence of biochemical and biomagnetic interactions in Alzheimer's disease: an MEG and MR spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Creatine; Female; Humans; Inosi | 2005 |
Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease.
Topics: Acetylglucosamine; Aged; Alzheimer Disease; Brain Chemistry; Choline; Creatine; Female; Glutamic Aci | 2005 |
[Proton spectroscopy in Alzheimer's disease and cognitive impairment not dementia: a community study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognition | 2005 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Anim | 2006 |
Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Central Nervous System; Homeostasis; Inositol; Mi | 2007 |
Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biopsy; Brain; Cognition Disorders; Creatine; Female; Humans | 2007 |
Identification of molecular compounds critical to Alzheimer's-like plaque formation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cells, Cultured; Chondroitin; Cytochalasin D; Dextran Sulf | 2007 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition Disorders; Cre | 2007 |
Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aspartic Acid; Cognition; Creatinine; Cross-Sectional St | 2007 |
Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amnesia; Aspartic Acid; Cerebral Cortex; Cognition Disorders; Creatine; Fem | 2007 |
Reproducibility of magnetic resonance spectroscopy in correlation with signal-to-noise ratio.
Topics: Aged; Alzheimer Disease; Artifacts; Aspartic Acid; Choline; Creatine; Female; Gyrus Cinguli; Humans; | 2007 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatinine; Female; gamma-Aminobutyric Ac | 1995 |
Comments on use of H-1 MR spectroscopy for diagnosis of probable Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Creatine; Humans; Inositol; Magnetic Resonance Spectr | 1995 |
Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Drug Design; Humans; In Vitro Techniques; Indicators an | 1994 |
Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Brain Chemistry; Female; Glucose; Humans; Inositol; Magnetic Resonan | 1994 |
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Choline; Creatine; Female; Humans; Inositol | 1993 |
1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Stud | 1996 |
Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Female; Gas Chromatography-Mass Spectrometry; Humans; Inositol; Male; Match | 1996 |
Evaluation of automated MR spectroscopy: application in Alzheimer disease.
Topics: Adult; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Humans; Inosito | 1995 |
Proton magnetic resonance spectroscopy in dementia of Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; | 1997 |
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female; | 1997 |
Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 1998 |
Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cattle; Inositol; Inositol 1,4,5-Trisphosphate; I | 1998 |
[Clinical uses of proton magnetic resonance spectroscopy of the brain].
Topics: AIDS Dementia Complex; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Diseases; Brain Disea | 1998 |
Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Mapping; Choline; Creatine; Female; Humans; Ino | 1998 |
Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Case-Control Studies; Cognition Disorders; Female | 1998 |
High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
Topics: Adult; Age Factors; Alzheimer Disease; Biomarkers; Brain; Brain Chemistry; Diagnosis, Differential; | 1999 |
Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Circular Dichroism; Humans; Inositol; Microscopy, | 2000 |
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde | 2000 |
Amyloid beta proteins inhibit Cl(-)-ATPase activity in cultured rat hippocampal neurons.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine Triphosphatases; Alzheimer Disease; Amyloid beta-P | 2001 |
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cognitio | 2001 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |
Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cell Membrane; Cells, Cultured; Cerebral Amyloid An | 2001 |
Down's syndrome fibroblasts exhibit enhanced inositol uptake.
Topics: Alzheimer Disease; Biological Transport; Cell Line; Choline; Chromosome Mapping; Chromosomes, Human, | 1990 |
Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Inositol; Male; Phosphatidylinositol 4,5 | 1987 |